Drug/Small Molecule:
thiabendazole

PharmGKB contains no dosing guidelines for this drug/small molecule. To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.

PharmGKB contains no drug labels with pharmacogenomic information for this drug/small molecule. To report a drug label with PGx, click here.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

This is a non-comprehensive list of genetic tests with pharmacogenetics relevance, typically submitted by the manufacturer and manually curated by PharmGKB. The information listed is provided for educational purposes only and does not constitute an endorsement of any listed test or manufacturer.

A more complete listing of genetic tests is found at the Genetic Testing Registry (GTR).

PGx Test Variants Assayed Gene?
2D structure from PubChem
provided by PubChem

Overview

Generic Names
  • 2-(1,3-thiazol-4-yl)-1h-benzimidazole
  • TBDZ
  • TBZ
  • Thiabendazol
  • Thiabendole
  • Thiabenzazole
  • Thiabenzole
  • Tiabendazol
  • Tiabendazole
Trade Names
  • Apl-Luster
  • Arbotect
  • Bioguard
  • Bovizole
  • Chemviron TK 100
  • Cropasal
  • Drawipas
  • Eprofil
  • Equivet TZ
  • Equizole
  • Hokustar hp
  • Hymush
  • Lombristop
  • Mertec
  • Mertect
  • Mertect 160
  • Mertect 340f
  • Mertect lsp
  • Metasol TK 10
  • Metasol TK 100
  • Mintesol
  • Mintezol
  • Minzolum
  • Mycozol
  • Nemacin
  • Nemapan
  • Omnizole
  • Ormogal
  • Polival
  • RPH
  • Sanaizol 100
  • Sistesan
  • Storite
  • TBZ 6
  • TBZ 60W
  • Tebuzate
  • Tecto
  • Tecto 10P
  • Tecto 40F
  • Tecto 60
  • Tecto B
  • Tecto rph
  • Testo
  • Thiaben
  • Thibendole
  • Thibenzol
  • Thibenzole
  • Thibenzole 200
  • Thibenzole att
  • Thiprazole
  • Tiabenda
  • Tibimix 20
  • Tobaz
  • Top form wormer
  • Triasox
  • Tubazole
Brand Mixture Names
  • Tresaderm Dermatologic Solution (Dexamethasone + Neomycin sulfate + Thiabendazole)

PharmGKB Accession Id:
PA164746466

Description

2-Substituted benzimidazole first introduced in 1962. It is active against a variety of nematodes and is the drug of choice for strongyloidiasis. It has CNS side effects and hepatototoxic potential. (From Smith and Reynard, Textbook of Pharmacology, 1992, p919)

Source: Drug Bank

Indication

For the treatment of strongyloidiasis (threadworm), cutaneous larva migrans (creeping eruption), visceral larva migrans, and trichinosis.

Source: Drug Bank

Other Vocabularies

Information pulled from DrugBank has not been reviewed by PharmGKB.

Pharmacology, Interactions, and Contraindications

Mechanism of Action

The precise mode of action of thiabendazole on the parasite is unknown, but it most likely inhibits the helminth-specific enzyme fumarate reductase.

Source: Drug Bank

Pharmacology

Thiabendazole is a fungicide and parasiticide. Thiabendazole is also a chelating agent, which means that it is used medicinally to bind metals in cases of metal poisoning, such as lead poisoning, mercury poisoning or antimony poisoning. Thiabendazole is vermicidal and/or vermifugal against Ascaris lumbricoides ("common roundworm"), Strongyloides stercoralis (threadworm), Necator americanus, Ancylostoma duodenale (hookworm), Trichuris trichiura (whipworm), Ancylostoma braziliense (dog and cat hookworm), Toxocara canis, Toxocara cati (ascarids), and Enterobius vermicularis (pinworm). Thiabendazole also suppresses egg and/or larval production and may inhibit the subsequent development of those eggs or larvae which are passed in the feces.

Source: Drug Bank

Absorption, Distribution, Metabolism, Elimination & Toxicity

Biotransformation

Hepatic. Metabolized almost completely to the 5-hydroxy form which appears in the urine as glucuronide or sulfate conjugates.

Source: Drug Bank

Absorption

Rapidly absorbed and peak plasma concentration is reached within 1 to 2 hours after the oral administration of a suspension. Some systemic absorption may occur from topical preparations applied to the skin.

Source: Drug Bank

Half-Life

The half-life for thiabendazole in both normal and anephric patients is 1.2 hours (range 0.9 to 2 hours). The half-life for the 5-hydroxythiabendazole metabolite in both normal and anephric patients is 1.7 hours (range 1.4 to 2 hours).

Source: Drug Bank

Toxicity

Overdosage may be associated with transient disturbances of vision and psychic alterations. The oral LD 50 is 3.6 g/kg, 3.1 g/kg and 3.8 g/kg in the mouse, rat, and rabbit respectively.

Source: Drug Bank

Route of Elimination

It is metabolized almost completely to the 5-hydroxy form which appears in the urine as glucuronide or sulfate conjugates.

Source: Drug Bank

Chemical Properties

Chemical Formula

C10H7N3S

Source: Drug Bank

Isomeric SMILES

c1ccc2c(c1)[nH]c(n2)c3cscn3

Source: OpenEye

Canonical SMILES

N1C2=CC=CC=C2N=C1C1=CSC=N1

Source: Drug Bank

Average Molecular Weight

201.248

Source: Drug Bank

Monoisotopic Molecular Weight

201.036067929

Source: Drug Bank

Genes that are associated with this drug in PharmGKB's database based on (1) variant annotations, (2) literature review, (3) pathways or (4) information automatically retrieved from DrugBank, depending on the "evidence" and "source" listed below.

No related genes are available.

Drug Interactions

Drug Description
thiabendazole Thiabendazole increases the effect and toxicity of theophylline (source: Drug Bank)
thiabendazole Thiabendazole increases the effect and toxicity of theophylline (source: Drug Bank)
thiabendazole Thiabendazole increases levels/toxicity of ramelteon (source: Drug Bank)
thiabendazole Thiabendazole increases levels/toxicity of ramelteon (source: Drug Bank)
thiabendazole The metabolism of Tacrine, a CYP1A2 substrate, may be reduced by strong CYP1A2 inhibitors such as Thiabendazole. Consider modifying therapy to avoid Tacrine toxicity. Monitor the efficacy and toxicity of Tacrine if Thiabendazole is initiated, discontinued or if the dose is changed. (source: Drug Bank)
thiabendazole Thiabendazole increases the effect and toxicity of theophylline (source: Drug Bank)
thiabendazole Thiabendazole increases the effect and toxicity of theophylline (source: Drug Bank)
acenocoumarol The strong CYP1A2 inhibitor, Thiabendazole, may increase the effects and toxicity of Acenocoumarol by decreasing Acenocoumarol metabolism and clearance. Monitor for changes in the therapeutic and adverse effects of Acenocoumarol if Thiabendazole is initiated, discontinued or dose changed. (source: Drug Bank)
alosetron The strong CYP1A2 inhibitor, Thiabendazole, may increase the effects and toxicity of Alosetron by decreasing Alosetron metabolism and clearance. Monitor for changes in the therapeutic and adverse effects of Alosetron if Thiabendazole is initiated, discontinued or dose changed. (source: Drug Bank)
aminophylline The strong CYP1A2 inhibitor, Thiabendazole, may increase the effects and toxicity of Aminophylline by decreasing Aminophylline metabolism and clearance. Monitor for changes in the therapeutic and adverse effects of Aminophylline if Thiabendazole is initiated, discontinued or dose changed. (source: Drug Bank)
betaxolol The strong CYP1A2 inhibitor, Thiabendazole, may increase the effects and toxicity of Betaxolol by decreasing Betaxolol metabolism and clearance. Monitor for changes in the therapeutic and adverse effects of Betaxolol if Thiabendazole is initiated, discontinued or dose changed (source: Drug Bank)
caffeine The strong CYP1A2 inhibitor, Thiabendazole, may increase the effects and toxicity of Caffeine by decreasing Caffeine metabolism and clearance. Monitor for changes in the therapeutic and adverse effects of Caffeine if Thiabendazole is initiated, discontinued or dose changed. (source: Drug Bank)
clomipramine The strong CYP1A2 inhibitor, Thiabendazole, may increase the effects and toxicity of Clomipramine by decreasing Clomipramine metabolism and clearance. Monitor for changes in the therapeutic and adverse effects of Clomipramine if Thiabendazole is initiated, discontinued or dose changed. (source: Drug Bank)
clozapine The strong CYP1A2 inhibitor, Thiabendazole, may increase the effects and toxicity of Clozapine by decreasing Clozapine metabolism and clearance. Monitor for changes in the therapeutic and adverse effects of Clozapine if Thiabendazole is initiated, discontinued or dose changed. (source: Drug Bank)
cyclobenzaprine The strong CYP1A2 inhibitor, Thiabendazole, may increase the effects and toxicity of Cyclobenzaprine by decreasing Cyclobenzaprine metabolism and clearance. Monitor for changes in the therapeutic and adverse effects of Cyclobenzaprine if Thiabendazole is initiated, discontinued or dose changed. (source: Drug Bank)
dacarbazine The strong CYP1A2 inhibitor, Thiabendazole, may increase the effects and toxicity of Dacarbazine by decreasing Dacarbazine metabolism and clearance. Monitor for changes in the therapeutic and adverse effects of Dacarbazine if Thiabendazole is initiated, discontinued or dose changed. (source: Drug Bank)
doxepin The strong CYP1A2 inhibitor, Thiabendazole, may increase the effects and toxicity of Doxepin by decreasing Doxepin metabolism and clearance. Monitor for changes in the therapeutic and adverse effects of Doxepin if Thiabendazole is initiated, discontinued or dose changed. (source: Drug Bank)
duloxetine The strong CYP1A2 inhibitor, Thiabendazole, may increase the effects and toxicity of Duloxetine by decreasing Duloxetine metabolism and clearance. Monitor for changes in the therapeutic and adverse effects of Duloxetine if Thiabendazole is initiated, discontinued or dose changed. (source: Drug Bank)
flutamide The strong CYP1A2 inhibitor, Thiabendazole, may increase the effects and toxicity of Flutamide by decreasing Flutamide metabolism and clearance. Monitor for changes in the therapeutic and adverse effects of Flutamide if Thiabendazole is initiated, discontinued or dose changed. (source: Drug Bank)
fluvoxamine The strong CYP1A2 inhibitor, Thiabendazole, may increase the effects and toxicity of Fluvoxamine by decreasing Fluvoxamine metabolism and clearance. Monitor for changes in the therapeutic and adverse effects of Fluvoxamine if Thiabendazole is initiated, discontinued or dose changed. (source: Drug Bank)
guanabenz The strong CYP1A2 inhibitor, Thiabendazole, may increase the effects and toxicity of Guanabenz by decreasing Guanabenz metabolism and clearance. Monitor for changes in the therapeutic and adverse effects of Guanabenz if Thiabendazole is initiated, discontinued or dose changed. (source: Drug Bank)
theophylline The strong CYP1A2 inhibitor, Thiabendazole, may increase the effects and toxicity of Theophylline by decreasing Theophylline metabolism and clearance. Monitor for changes in the therapeutic and adverse effects of Theophylline if Thiabendazole is initiated, discontinued or dose changed. (source: Drug Bank)
thiothixene The strong CYP1A2 inhibitor, Thiabendazole, may increase the effects and toxicity of Thiothixene by decreasing Thiothixene metabolism and clearance. Monitor for changes in the therapeutic and adverse effects of Thiothixene if Thiabendazole is initiated, discontinued or dose changed. (source: Drug Bank)
tizanidine The strong CYP1A2 inhibitor, Thiabendazole, may increase the effects and toxicity of Tizanidine by decreasing Tizanidine metabolism and clearance. Monitor for changes in the therapeutic and adverse effects of Tizanidine if Thiabendazole is initiated, discontinued or dose changed. (source: Drug Bank)
trifluoperazine The strong CYP1A2 inhibitor, Thiabendazole, may increase the effects and toxicity of Trifluoperazine by decreasing Trifluoperazine metabolism and clearance. Monitor for changes in the therapeutic and adverse effects of Trifluoperazine if Thiabendazole is initiated, discontinued or dose changed. (source: Drug Bank)
thiabendazole The strong CYP1A2 inhibitor, Thiobendazole, may decrease the metabolism and clearance of Thiothixene, a CYP1A2 substrate. Consider alternate therapy or monitor for changes in Thiothixene therapeutic and adverse effects if Thiobendazole is initiated, discontinued or dose changed. (source: Drug Bank)
thiabendazole The strong CYP1A2 inhibitor, Thiobendazole, may decrease the metabolism and clearance of Thiothixene, a CYP1A2 substrate. Consider alternate therapy or monitor for changes in Thiothixene therapeutic and adverse effects if Thiobendazole is initiated, discontinued or dose changed. (source: Drug Bank)
thiabendazole Thiabendazole may decrease the metabolism and clearance of Tizanidine. Consider alternate therapy or use caution during co-administration. (source: Drug Bank)

LinkOuts

Web Resource:
Wikipedia
National Drug Code Directory:
0006-3331-60
DrugBank:
DB00730
PDB:
TMG
ChEBI:
45979
KEGG Drug:
D00372
PubChem Compound:
5430
PubChem Substance:
46505131
7847438
Drugs Product Database (DPD):
140228
ChemSpider:
5237
HET:
TMG
Therapeutic Targets Database:
DAP000664
FDA Drug Label at DailyMed:
591fd65c-3111-4f5c-dbb5-c67e07ad28fb

Clinical Trials

These are trials that mention thiabendazole and are related to either pharmacogenetics or pharmacogenomics.

Common Searches

Search PubMed
Search Medline Plus
Search PubChem
Search CTD

Sources for PharmGKB drug information: DrugBank, Open Eye Scientific Software.